Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL4957341 | 0.97 | KDM4E (0.58) | KDM4EGAAALDH1A1POLBEIF4A3 | |
| SCHEMBL31273523 | 0.88 | EIF4A3 (0.66) | KDM4EGAAALDH1A1POLBEIF4A3 | |
| SCHEMBL30547869 | 0.80 | EIF4A3 (0.77) | KDM4EGAAALDH1A1EIF4A3HPGD | |
| SCHEMBL3643479 | 0.80 | EIF4A3 (0.77) | KDM4EGAAALDH1A1EIF4A3HPGD | |
| SCHEMBL10969986 | 0.80 | KDM4E (0.66) | KDM4EGAAALDH1A1POLBHPGD | |
| SCHEMBL31222329 | 0.79 | ALDH1A1 (0.74) | KDM4EGAAALDH1A1POLBHPGD | |
| SCHEMBL22184893 | 0.78 | IDH1 (0.42) | KDM4EALDH1A1EIF4A3HPGDHSD17B10 | |
| SCHEMBL29415468 | 0.78 | KDM4E (0.63) | KDM4EGAAALDH1A1POLBHPGD | |
| SCHEMBL2806050 | 0.78 | KDM4E (0.63) | KDM4EGAAALDH1A1POLBHPGD | |
| SCHEMBL2310250 | 0.76 | F7 (0.63) | KDM4EGAAALDH1A1POLBGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024061960-A1 | VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO) | ALFASIGMA S.P.A. (IT) | 2024-03-28 | — | — | WO | claimed |
| EP-3661518-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | Theravance Biopharma R&D IP, LLC (US) | 2020-06-10 | — | — | EP | claimed |
| WO-2019027881-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | claimed |
| WO-2010120695-A2 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| EP-2160188-A2 | PROKINETIC AGENT FOR BOWEL PREPARATION | Theravance, Inc. (US) | 2010-03-10 | — | — | EP | claimed |
| WO-2008143916-A2 | PROKINETIC AGENT FOR BOWEL PREPARATION | THERAVANCE, INC. (US) | 2008-11-27 | — | — | WO | claimed |
| EP-1874766-A2 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | Theravance, Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1807422-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | Theravance, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| EP-1807423-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | Theravance, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| EP-1735304-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006108127-A2 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE, INC. (US) | 2006-10-12 | — | — | WO | claimed |
| WO-2006052640-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| WO-2006052889-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | claimed |
| WO-2024061960-A1 | VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO) | ALFASIGMA S.P.A. (IT) | 2024-03-28 | — | — | WO | disclosed |
| EP-3661518-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | Theravance Biopharma R&D IP, LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019027881-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2006052889-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052640-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | disclosed |